APRE
Price
$1.55
Change
+$0.05 (+3.33%)
Updated
Sep 5 closing price
Capitalization
9.03M
EYPT
Price
$14.01
Change
+$2.13 (+17.93%)
Updated
Sep 5 closing price
Capitalization
965.67M
52 days until earnings call
Interact to see
Advertisement

APRE vs EYPT

Header iconAPRE vs EYPT Comparison
Open Charts APRE vs EYPTBanner chart's image
Aprea Therapeutics
Price$1.55
Change+$0.05 (+3.33%)
Volume$19.82K
Capitalization9.03M
EyePoint Pharmaceuticals
Price$14.01
Change+$2.13 (+17.93%)
Volume$1.92M
Capitalization965.67M
APRE vs EYPT Comparison Chart in %
Loading...
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APRE vs. EYPT commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and EYPT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (APRE: $1.55 vs. EYPT: $14.01)
Brand notoriety: APRE and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 40% vs. EYPT: 301%
Market capitalization -- APRE: $9.03M vs. EYPT: $965.67M
APRE [@Biotechnology] is valued at $9.03M. EYPT’s [@Biotechnology] market capitalization is $965.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than APRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 3 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • APRE’s TA Score: 3 bullish, 6 bearish.
  • EYPT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than APRE.

Price Growth

APRE (@Biotechnology) experienced а -0.96% price change this week, while EYPT (@Biotechnology) price change was +21.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($966M) has a higher market cap than APRE($9.03M). EYPT YTD gains are higher at: 88.054 vs. APRE (-52.888). APRE has higher annual earnings (EBITDA): -14.77M vs. EYPT (-172.05M). EYPT has more cash in the bank: 256M vs. APRE (16.5M). APRE has less debt than EYPT: APRE (0) vs EYPT (21.8M). EYPT has higher revenues than APRE: EYPT (51.9M) vs APRE (0).
APREEYPTAPRE / EYPT
Capitalization9.03M966M1%
EBITDA-14.77M-172.05M9%
Gain YTD-52.88888.054-60%
P/E RatioN/AN/A-
Revenue051.9M-
Total Cash16.5M256M6%
Total Debt021.8M-
FUNDAMENTALS RATINGS
APRE vs EYPT: Fundamental Ratings
APRE
EYPT
OUTLOOK RATING
1..100
6382
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10078
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
8636
P/E GROWTH RATING
1..100
418
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (13) in the null industry is somewhat better than the same rating for EYPT (61) in the Pharmaceuticals Major industry. This means that APRE’s stock grew somewhat faster than EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (78) in the Pharmaceuticals Major industry is in the same range as APRE (100) in the null industry. This means that EYPT’s stock grew similarly to APRE’s over the last 12 months.

EYPT's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as APRE (98) in the null industry. This means that EYPT’s stock grew similarly to APRE’s over the last 12 months.

EYPT's Price Growth Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for APRE (86) in the null industry. This means that EYPT’s stock grew somewhat faster than APRE’s over the last 12 months.

APRE's P/E Growth Rating (4) in the null industry is in the same range as EYPT (18) in the Pharmaceuticals Major industry. This means that APRE’s stock grew similarly to EYPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APREEYPT
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 6 days ago
89%
Bullish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
Bullish Trend 5 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CWT47.090.40
+0.86%
California Water Service
TRX0.40N/A
+0.65%
TRX Gold Corp
EC9.080.04
+0.44%
Ecopetrol SA
LINC19.38-0.09
-0.46%
Lincoln Educational Services Corp
MSN0.41-0.01
-2.26%
Emerson Radio Corp

APRE and

Correlation & Price change

A.I.dvisor tells us that APRE and EYPT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and EYPT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
+3.33%
EYPT - APRE
32%
Poorly correlated
+17.93%
CABA - APRE
32%
Poorly correlated
+10.39%
PRQR - APRE
31%
Poorly correlated
+2.51%
ERAS - APRE
29%
Poorly correlated
+8.78%
SCPH - APRE
29%
Poorly correlated
-0.18%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with OCUL. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+17.93%
OCUL - EYPT
65%
Loosely correlated
+7.09%
LYRA - EYPT
58%
Loosely correlated
-2.70%
BEAM - EYPT
54%
Loosely correlated
+12.62%
ATHE - EYPT
54%
Loosely correlated
N/A
RXRX - EYPT
52%
Loosely correlated
+1.99%
More